Recently, a subgroup analysis of the AMLSG HD98D clinical trial showed that AML patients bearing NPM1-, but not FLT3-mutations had lower relapse incidence and better overall survival after induction chemotherapy combined with ATRA, suggesting a role for ATRA in the treatment of non-M3 AML [6]. Here, NPM1 is linked to acute myeloid leukemia.